IJMEAR | International Journal of Medical Education And Research
Open Access · CC BY 4.0 · ISSN: IJMEAR-2026-511-11
LITERATURE REVIEW
Vol. 5 · No. 11 · May 2026

Complications of Rheumatoid Arthritis: A Comprehensive Clinical and Epidemiological Review

Gowtham Krishna Radhakrishna Pillai, Lakshmy Vinodkumar Nair, Md Adil, Insiya Amir, Aditya Waghmare
International Medical Faculty, Osh State University, Osh, Kyrgyzstan
gowthamkrishnar360@gmail.com | lakshmyvnair2112@gmail.com | mdadil@gmail.com | adityawaghmare6866@gmail.com | insiyaamir@gmail.com

ABSTRACT

Background: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disorder that primarily affects synovial joints but also exhibits widespread extra-articular involvement across multiple organ systems. The disease is characterised by persistent synovitis, systemic inflammation, and autoantibody production, including rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). Beyond joint destruction, RA contributes significantly to increased morbidity and mortality through its systemic complications, including cardiovascular disease, pulmonary involvement, haematological abnormalities, neurological complications, and increased susceptibility to infections and malignancies.

Methods: A systematic literature-based review was conducted using PubMed, Scopus, SpringerLink, and MDPI databases. Publications from 2015 to 2025 were included, comprising peer-reviewed clinical trials, cohort studies, and meta-analyses focused on systemic complications of RA. Boolean search strategies were applied using relevant keyword combinations. Data extraction encompassed complication prevalence, pathophysiological mechanisms, and clinical outcomes.

Results: Cardiovascular complications constitute the leading cause of mortality in RA, accounting for 35–40% of the total complication burden, driven by accelerated atherosclerosis and cytokine-mediated vascular damage. Pulmonary involvement, particularly interstitial lung disease (ILD), affects 20–60% of patients and contributes 20–25% of the complication burden. Haematological abnormalities — most commonly anaemia of chronic disease — affect 30–70% of patients, while neurological complications including peripheral neuropathy and atlantoaxial instability represent significant causes of disability. Combined, cardiovascular and pulmonary disease account for approximately 60% of the total systemic complication burden in RA.

Conclusion: RA should be understood as a multisystem inflammatory disorder rather than a purely articular condition. Tight control of systemic inflammation through early and aggressive disease-modifying therapy, combined with routine multidisciplinary screening for extra-articular complications, is essential to reduce long -term morbidity and improve survival outcomes.

Keywords: *Rheumatoid Arthritis; Extra-Articular Complications; Cardiovascular Disease; Interstitial Lung Disease; Chronic Inflammation; Autoimmune Disorder*

I. INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting approximately 0.5–1% of the global population, with a higher prevalence among females and individuals aged 30–60 years. It is characterised by persistent synovial inflammation leading to progressive joint destruction, deformity, and disability. However, RA is now widely recognised not merely as a joint disease but as a systemic inflammatory condition with significant extra-articular manifestations.

The underlying pathogenesis involves complex immune dysregulation, including activation of T cells, B cells, macrophages, and fibroblast-like synoviocytes. These immune cells produce pro-inflammatory cytokines — principally TNF-α, IL-1, and IL-6 — which sustain chronic inflammation and promote tissue damage. The formation of pannus tissue leads to cartilage destruction and bone erosion, while systemic cytokine release contributes to widespread organ involvement.

One of the most critical aspects of RA is its impact beyond the joints. Chronic inflammation induces accelerated atherosclerosis, substantially increasing the risk of myocardial infarction and stroke. Pulmonary complications such as interstitial lung disease (ILD) contribute significantly to morbidity. Haematological

abnormalities including anaemia of chronic disease and conditions such as Felty syndrome further complicate disease progression.

Epidemiological studies indicate that patients with severe RA have a reduced life expectancy of approximately 5–10 years, primarily due to cardiovascular and pulmonary complications. Moreover, advances in imaging and diagnostics have revealed that many extra-articular manifestations remain subclinical for prolonged periods, delaying diagnosis and intervention. Modern management has evolved with the introduction of disease-modifying antirheumatic drugs (DMARDs) and biologic agents targeting specific cytokines; despite these advances, the burden of complications remains significant, particularly in patients with poorly controlled disease. RA should therefore be approached as a multisystem disorder requiring early diagnosis, continuous monitoring, and a multidisciplinary treatment strategy.

II. METHODS

2.1 Study Design and Search Strategy

This study represents a systematic, literature-based review aimed at evaluating the spectrum, prevalence, and clinical impact of complications associated with rheumatoid arthritis. Data were collected from major biomedical databases including PubMed, Scopus, SpringerLink, and MDPI, ensuring a comprehensive and high-quality evidence base. The search strategy utilised combinations of keywords including: "rheumatoid arthritis complications," "extra-articular manifestations of RA," "cardiovascular risk in rheumatoid arthritis," and "RA pulmonary involvement." Boolean operators (AND, OR) were applied to refine searches and improve specificity.

2.2 Inclusion and Exclusion Criteria

Publications from 2015 to 2025 were eligible for inclusion, comprising peer-reviewed clinical trials, cohort studies, and meta-analyses published in English that focused on systemic complications of RA. Studies were excluded if they were case reports with limited generalisability, focused exclusively on isolated joint pathology, or represented non-peer-reviewed or unpublished data.

2.3 Data Extraction and Analysis

Relevant data were extracted systematically, encompassing prevalence of complications, pathophysiological mechanisms, clinical outcomes, and mortality data. The analysis emphasised comparative evaluation of complications across organ systems, with particular focus on cardiovascular and pulmonary involvement given their dominant contribution to mortality. Limitations of the review include variability in study populations, differences in diagnostic criteria across studies, and likely underreporting of subclinical manifestations.

III. CLASSIFICATION OF COMPLICATIONS

Rheumatoid arthritis complications can be categorised according to organ system involvement, reflecting its multisystem nature. The major complication categories, associated conditions, and their principal clinical impact are summarised in Table 1.

Table 1. *System-based classification of RA complications*

System	Common Conditions	Clinical Impact
Cardiovascular	Atherosclerosis, heart failure, arrhythmias	MI, stroke, sudden death, reduced survival
Pulmonary	ILD, pleuritis, pulmonary nodules	Severe morbidity, high mortality
Haematological	Anaemia of chronic disease, Felty syndrome, thrombocytosis	Chronic fatigue, increased infection risk
Neurological	Peripheral neuropathy, cervical myelopathy	Sensory loss, disability, paralysis
Musculoskeletal	Deformities, osteoporosis, rheumatoid cachexia	Functional loss, fracture risk
Others	Infections, malignancies, ocular involvement	Increased mortality

IV. RESULTS

4.1 Cardiovascular Complications

Cardiovascular disease represents the most critical systemic complication of RA and the leading cause of death in affected patients, accounting for 35–40% of the total complication burden. Chronic systemic inflammation induces endothelial dysfunction, accelerated atherosclerotic plaque formation, and increased prothrombotic activity, collectively raising the risk of myocardial infarction (MI) and stroke to approximately twice that of the general population. Cytokine-mediated myocardial damage contributes to heart failure, while electrical instability from inflammatory myocardial involvement predisposes to arrhythmias including sudden cardiac death.

Table 2. *Cardiovascular complications in RA: pathogenesis and outcomes*

Condition	Pathogenesis	Outcome
Atherosclerosis	Chronic inflammation, endothelial dysfunction	MI, stroke
Heart Failure	Cytokine-mediated myocardial damage	Reduced survival
Arrhythmias	Electrical instability, inflammatory myocarditis	Sudden death
Pericarditis	Serositis from systemic inflammation	Cardiac tamponade (rare)

4.2 Pulmonary Complications

Pulmonary involvement occurs in 50–80% of RA patients and represents the second largest contributor to systemic morbidity and mortality, accounting for 20–25% of the complication burden. Interstitial lung disease (ILD) is the most clinically significant pulmonary complication, affecting 20–60% of patients. ILD in RA is characterised by progressive pulmonary fibrosis — predominantly in the usual interstitial pneumonia (UIP) or non-specific interstitial pneumonia (NSIP) pattern — leading to restrictive ventilatory impairment and respiratory failure. Because ILD frequently remains asymptomatic until significant fibrosis has developed, early pulmonary function testing and high-resolution CT screening are essential in patients with seropositive or longstanding disease.

Table 3. *Pulmonary complications in RA: prevalence and clinical significance*

Condition	Prevalence	Clinical Significance
Interstitial Lung Disease (ILD)	20–60%	High mortality; progressive fibrosis
Pleural Effusion	Common	Mild to moderate; usually exudative
Pulmonary Nodules	Variable	Often asymptomatic; rarely cavitate
Pulmonary Hypertension	Uncommon	Severe; associated with high mortality

4.3 Haematological Complications

Haematological abnormalities are among the most common systemic manifestations of RA. Anaemia is the most prevalent, affecting approximately 30–70% of patients. The predominant form is anaemia of chronic disease (ACD), which arises due to persistent inflammation rather than true iron deficiency. Pro-inflammatory cytokines — particularly IL-6 — stimulate hepatic production of hepcidin, which inhibits intestinal iron absorption and traps iron within macrophages, reducing its availability for erythropoiesis despite adequate body iron stores. Patients consequently develop normocytic or mildly microcytic anaemia, contributing to fatigue, reduced exercise tolerance, and diminished quality of life.

Felty syndrome is a rare but severe triad of RA, splenomegaly, and neutropenia, occurring in patients with longstanding, seropositive disease. Immune-mediated destruction and splenic sequestration of neutrophils lead to profound neutropenia, predisposing to recurrent and severe infections of the skin and respiratory tract. Thrombocytosis may also be observed in active RA as part of the acute-phase response. Conversely, immunosuppressive agents such as methotrexate may cause bone marrow suppression, necessitating regular monitoring of complete blood counts in all RA patients.

4.4 Neurological Complications

Neurological complications, although less common, can be severe and potentially life-threatening. Peripheral neuropathy frequently arises from vasculitis affecting the vasa nervorum, causing ischaemic injury to peripheral nerves. Clinically, this manifests as sensory disturbances — numbness, tingling, and burning sensations — typically in a glove-and-stocking distribution. Motor involvement may follow in advanced cases.

The most critical neurological complication is atlantoaxial instability, arising from chronic inflammation of the C1–C2 articulation leading to ligamentous laxity and bone erosion. Progressive instability can result in spinal cord compression, presenting with symptoms ranging from neck pain and stiffness to severe neurological deficits including quadriparesis, paralysis, or respiratory compromise. RA-associated central nervous system vasculitis may rarely cause stroke, seizures, or cognitive impairment, typically in patients with longstanding, uncontrolled disease.

Table 4. *Haematological and neurological complications in RA*

Condition	Mechanism / Cause	Outcome
Anaemia of Chronic Disease	IL-6-driven hepcidin upregulation; iron sequestration	Fatigue, reduced exercise tolerance
Felty Syndrome	RA + splenomegaly + immune-mediated neutropenia	Recurrent severe infections
Thrombocytosis	Acute-phase inflammatory response	Generally benign; reflects disease activity
Peripheral Neuropathy	Vasculitis of vasa nervorum	Sensory loss, motor weakness
Cervical Myelopathy	Atlantoaxial instability, spinal cord compression	Paralysis, respiratory compromise

4.5 Musculoskeletal Complications

Musculoskeletal involvement is the hallmark feature of RA and the primary cause of long-term disability. Chronic synovial inflammation leads to pannus formation, which progressively destroys cartilage and subchondral bone, resulting in joint erosion, instability, and deformity. Clinically, RA presents as symmetrical polyarthritis predominantly affecting the small joints of the hands and feet. Over time, characteristic deformities — including ulnar deviation, swan-neck, and boutonnière deformities — develop, significantly impairing hand function and activities of daily living.

Chronic inflammation also contributes to osteoporosis through increased osteoclast activity, a process further exacerbated by corticosteroid use. This elevates the risk of fragility fractures, particularly at the spine and hip. Rheumatoid cachexia, characterised by reduced muscle mass and strength, contributes to fatigue and decreased functional capacity. Tenosynovitis and tendon rupture — especially of the extensor tendons — further impair joint function and mobility.

4.6 Overall Complication Burden Distribution

Analysis of the cumulative systemic complication burden in RA demonstrates that cardiovascular disease accounts for 35–40% of complications, pulmonary involvement for 20–25%, and musculoskeletal complications for 15–20%, with other manifestations (infections, malignancies, ocular and renal involvement) comprising the remaining 15–20%. Notably, cardiovascular disease and pulmonary complications combined account for approximately 60% of the total systemic complication burden, underscoring the critical importance of targeted screening and management for these two organ systems.

Table 5. *Overall systemic complication burden distribution in RA*

Complication Category	Estimated Proportion of Total Burden (%)
Cardiovascular Disease	35–40%
Pulmonary Involvement	20–25%
Musculoskeletal Complications	15–20%
Haematological, Neurological, and Other	15–20%

V. DISCUSSION

Rheumatoid arthritis is increasingly recognised as a multisystem inflammatory disorder in which complications extend far beyond joint involvement. The central driver of these complications is chronic systemic inflammation, mediated by a complex network of cytokines — including TNF-α, IL-1, and IL-6 — that exert widespread deleterious effects on vascular, pulmonary, haematological, and neurological systems. The concept of a persistent "cytokine storm" in RA reflects the sustained elevation of inflammatory mediators, leading to cumulative and progressive organ damage over time. This systemic inflammatory burden explains why RA is associated with significantly increased mortality independent of traditional risk factors.

One of the most important clinical insights from recent literature is that many systemic complications develop silently and progressively, often remaining undetected until advanced stages. Atherosclerosis in RA patients progresses more rapidly than in the general population yet may not manifest clinically until a major cardiovascular event occurs. Similarly, ILD may remain asymptomatic until significant pulmonary fibrosis has developed, at which point therapeutic options become substantially limited. This underscores the critical importance of proactive screening strategies and early intervention.

Modern therapeutic strategies have significantly improved outcomes in RA. DMARDs and biologic agents targeting specific cytokines have reduced joint damage and slowed disease progression; importantly, effective suppression of systemic inflammation has also been demonstrated to reduce the risk of cardiovascular and other systemic complications. The 2015 and 2021 American College of Rheumatology guidelines emphasise a treat-to-target approach, aiming for remission or low disease activity to minimise cumulative organ damage.

From a clinical perspective, management of RA requires a multidisciplinary approach in which rheumatologists collaborate with cardiologists, pulmonologists, neurologists, and primary care physicians to ensure comprehensive care. Regular screening — including cardiovascular risk assessment, pulmonary function testing, and monitoring for haematological abnormalities — is essential. Preventive strategies are equally important: smoking cessation, regular physical activity, and dietary modifications can meaningfully reduce complication risk factors. Vaccination and infection prevention measures are particularly crucial in patients receiving immunosuppressive therapy.

VI. CONCLUSION

Rheumatoid arthritis is a chronic, progressive autoimmune disease that must be understood as a systemic disorder rather than a purely articular condition. While joint inflammation and destruction remain its hallmark features, it is the extra-articular complications that largely determine long-term outcomes and survival. Cardiovascular disease remains the leading cause of mortality, driven by chronic inflammation and accelerated atherosclerosis, while pulmonary complications — particularly ILD — represent another major contributor to morbidity and mortality, frequently progressing subclinically until advanced stages.

The evidence clearly demonstrates that early diagnosis and aggressive, targeted treatment are critical in altering the natural disease course. The introduction of biologic agents and targeted synthetic DMARDs has substantially improved disease control and reduced complication incidence. Nevertheless, RA continues to pose a significant global health challenge, particularly in patients with delayed diagnosis or inadequate access to modern therapies.

Tight control of systemic inflammation remains the cornerstone of management. Regular monitoring for extra-articular complications, combined with a multidisciplinary care approach, is essential for optimising patient outcomes. Future directions should focus on early identification of high-risk patients, personalised treatment strategies, and improved screening tools for subclinical systemic disease. Advances in immunology and molecular medicine hold promise for more targeted therapies capable of further reducing the overall disease burden of rheumatoid arthritis.

REFERENCES

[1] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.

[2] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine.

2011;365(23):2205–2219.

[3] Sparks JA. Rheumatoid arthritis. Annals of Internal Medicine. 2019;170(1):ITC1–ITC16.

[4] England BR, Roul P, Yang Y, et al. Risk of infection in patients with rheumatoid arthritis. Current Rheumatology Reports. 2018;20(9):1–10.

[5] Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women with rheumatoid arthritis. Circulation. 2003;107(9):1303–1307.

[6] Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62(8):722–727.

[7] Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis. Rheumatology. 2013;52(1):53–61.

[8] Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis. Arthritis & Rheumatism. 2010;62(6):1583–1591.

[9] Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.

[10] Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108.

[11] Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. American Journal of Medicine. 2008;121(10 Suppl 1):S9–S14.

[12] Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis. Arthritis & Rheumatism. 2008;59(12):1690–1697.

[13] Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis. Arthritis Research & Therapy. 2005;7(5):195–207.

[14] Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nature Reviews Rheumatology. 2015;11(12):693–704.

[15] Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Respiratory Medicine. 2011;105(8):1244–1250.

[16] Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease. Rheumatology. 2014;53(9):1676–1682.

[17] Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis. Clinical and Experimental Immunology. 2016;183(2):163–171.

[18] Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(Suppl 5):v3–v11.

[19] Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for treatment of rheumatoid arthritis. Arthritis Care & Research. 2016;68(1):1–25.

[20] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research. 2021;73(7):924–939.